X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Hoechst 33342 Fluorescent Nucleic Acid Stain antibody

RRID:AB_2651135

Antibody ID

AB_2651135

Target Antigen

Vendor

ImmunoChemistry technologies

Cat Num

639

Proper Citation

(ImmunoChemistry technologies Cat# 639, RRID:AB_2651135)

Clonality

unknown

Comments

Please note, this is not an antibody, it is a fluorescent stain

Publications that use this research resource

Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.

  • Tankiewicz-Kwedlo A
  • Br. J. Pharmacol.
  • 2017 Nov 22

Literature context: emistry technologies, Cat# 639, RRID:AB_2651135). Cells were imaged with a BD P


Abstract:

BACKGROUND AND PURPOSE: Bruton's tyrosine kinase (Btk) is a non-receptor tyrosine kinase involved in the activation of signalling pathways responsible for cell maturation and viability. Btk has previously been reported to be overexpressed in colon cancers. This kind of cancer is often accompanied by anaemia, which is treated with an erythropoietin supplement. The goal of the present study was to assess the effects of combination therapy with erythropoietin β (Epo) and LFM-A13 (Btk inhibitor) on colon cancer in in vitro and in vivo models. EXPERIMENTAL APPROACH: DLD-1 and HT-29 human colon adenocarcinoma cells were cultured with Epo and LFM-A13. Cell number and viability, and mRNA and protein levels of Epo receptors, Btk and Akt were assessed. Nude mice were inoculated with adenocarcinoma cells and treated with Epo and LFM-A13. KEY RESULTS: The combination of Epo and LFM-A13 mostly exerted a synergistic inhibitory effect on colon cancer cell growth. The therapeutic scheme used effectively killed the cancer cells and attenuated the Btk signalling pathways. Epo + LFM-A13 also prevented the normal process of microtubule assembly during mitosis by down-regulating the expression of Polo-like kinase 1. The combination of Epo and LFM-A13 significantly reduced the growth rate of tumour cells, while it showed high safety profile, inducing no nephrotoxicity, hepatotoxicity or changes in the haematological parameters. CONCLUSION AND IMPLICATIONS: Epo significantly enhances the antitumour activity of LFM-A13, indicating that a combination of Epo and LFM-A13 has potential as an effective therapeutic approach for patients with colorectal cancer.

Diverse stimuli engage different neutrophil extracellular trap pathways.

  • Kenny EF
  • Elife
  • 2017 Jun 2

Literature context: try: 639, RRID:AB_2651135) and mount


Abstract:

Neutrophils release neutrophil extracellular traps (NETs) which ensnare pathogens and have pathogenic functions in diverse diseases. We examined the NETosis pathways induced by five stimuli; PMA, the calcium ionophore A23187, nigericin, Candida albicans and Group B Streptococcus. We studied NET production in neutrophils from healthy donors with inhibitors of molecules crucial to PMA-induced NETs including protein kinase C, calcium, reactive oxygen species, the enzymes myeloperoxidase (MPO) and neutrophil elastase. Additionally, neutrophils from chronic granulomatous disease patients, carrying mutations in the NADPH oxidase complex or a MPO-deficient patient were examined. We show that PMA, C. albicans and GBS use a related pathway for NET induction, whereas ionophores require an alternative pathway but that NETs produced by all stimuli are proteolytically active, kill bacteria and composed mainly of chromosomal DNA. Thus, we demonstrate that NETosis occurs through several signalling mechanisms, suggesting that extrusion of NETs is important in host defence.

Funding information:
  • NIGMS NIH HHS - R35 GM118112()